COVER STORY / ADVERTISING FEATURE


MeMed BV converts the levels of three host immune proteins into a simple score indicating the likelihood of a bacterial immune response or co-infection versus a likely viral immune response.


Utilising existing infrastructure The Access MeMed BV assay is available on Beckman Coulter’s DxI 9000 and Access 2 immunoassay analysers. It utilises existing laboratory infrastructure to provide differentiation between bacterial and viral infections, with results available in approximately 15 minutes on the DxI 9000 and about 22 minutes on the Access 2. The assay supports timely, evidence-based clinical decision-making and integrates into standard laboratory workflows to deliver rapid and reliable results. Reflecting on the clinical and


operational impact, Melissa Naiman, Senior Director, Medical & Scientific Affairs - Acute Care at Beckman Coulter Diagnostics, noted that: “By delivering rapid, highly reliable bacterial and viral differentiation on routine immunoassay systems, we’re empowering care teams with the timely insights they need to guide appropriate treatment decisions, while optimising laboratory efficiency using existing workflows.” The broader significance of this


approach is echoed by MeMed leadership. Eran Eden, CEO and Co-founder of MeMed, emphasised that: “This collaboration with Beckman Coulter significantly accelerates our mission to make host-response testing available at scale. The MeMed BV test has repeatedly demonstrated its ability to improve clinical decision-making, empower clinicians to reduce unnecessary antibiotic use, and support antimicrobial stewardship. This is backed by robust clinical and real-world evidence, including emerging evidence supporting its value in suspected sepsis management among high-risk patient populations. Making the assay available on high- throughput laboratory analysers allows healthcare systems to unlock those benefits for far more patients.”


Consistent accuracy MeMed BV performance has been validated in multi-national, double-blind clinical studies and real-world settings enrolling more than 20,000 subjects in Europe, Israel and the United States (references available). These studies have consistently demonstrated compelling performance results in different clinical settings, age groups, and patients with different clinical syndromes. Recent real-world studies across


nearly 6,000 adult and paediatric patients found that clinicians face uncertainty about antibiotic prescribing in approximately 16–29% of cases. Following receipt of MeMed BV results, physicians reported that the test supported or changed clinical decision-making in approximately 82–87% of cases. In prior blinded multicentre validation studies, MeMed BV demonstrated up to 99% negative predictive value (NPV) as an aid in excluding bacterial infection. The growing clinical interest in host-


response diagnostics is also reflected in recent NHS initiatives in the UK, where NHS England funded a multicentre paediatric trial evaluating rapid MeMed BV testing in emergency departments. Clinicians reported that the 15-minute test supported faster treatment decisions in children with serious conditions including meningitis and sepsis, while also helping reduce unnecessary antibiotic use by providing more rapid information about whether infections were viral or bacterial.


Case study A woman in her 40s, a healthcare worker, presented to the emergency department at Johns Hopkins Hospital with three days of high fever and body aches. Although her examination and initial workup were not strongly suggestive of


severe bacterial infection, the physician ordered a MeMed BV test to support clinical assessment. The test returned a score of 100, indicating a high likelihood of bacterial infection or bacterial co- infection. While discharge was initially being


considered, the MeMed BV result prompted the care team to keep the patient for observation. Within one hour, her condition worsened rapidly, progressing to septic shock. Imaging later revealed acute pyelonephritis, and blood and urine cultures subsequently grew Escherichia coli. She was admitted to the ICU, stabilised by day two and discharged home on day three. As noted by Professor Edana Mann of


the Johns Hopkins Hospital Emergency Department, the BV assay provided actionable information that standard laboratories could not, directly altering the patient’s trajectory; without it, the patient might have been discharged prior to her deterioration, delaying recognition of life-threatening sepsis.


References supplied and are available on request from info@pathologyinpractice.com.


EUPublicRelations@beckman.com htps://www.beckmancoulter.com/en/ products/immunoassay/memed-bv


June 2026 WWW.PATHOLOGYINPRACTICE.COM 7


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56